Vertex Ventures HC, a global healthcare investment firm led by women, has announced the launch of its third and largest fund of $200M, Fund III. The primary objective of Fund III is to back life sciences and medical technology companies focused on driving advancements in healthcare anad enhancing patient outcomes.
“As technology continues to reshape industries and science continues to advance, VVHC recognizes the tremendous potential of companies that hold promise for transforming healthcare and driving societal impact,” said Lori Hu, Managing Director, San Francisco. “As one of the few women-led funds in the healthcare sector, we are proud of our track record of success in supporting visionary entrepreneurs from company formation through exit.”
With a diversified investment strategy centered on scientific excellence, Vertex Ventures HC is led by Managing Directors Lori Hu and Christine Brennan. Both possess extensive experience in investing and operations, having led multiple investments resulting in successful exits through mergers and acquisitions (M&A) or initial public offerings (IPO). The firm places a strong emphasis on long-term growth and actively promotes diversity at the board and executive levels, while also nurturing teams for sustainable success.
Christine Brennan, PhD, Managing Director, Boston, commented: “With our third fund, we will continue to fuel the growth and advancement of medicines by providing capital, strategic guidance, and invaluable expertise to companies developing cutting-edge solutions and to weather the ups and downs of market cycles.”
Fund III will primarily target early-stage companies that demonstrate disruptive technologies, breakthrough research, and a clear path toward the development of new treatments. Leveraging its extensive network of industry experts, entrepreneurs, and researchers, Vertex Ventures HC aims to provide portfolio companies with access to valuable resources, strategic partnerships, and mentorship opportunities.
